Study summary

The purpose of this study was to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB.

This study will also evaluated the safety and tolerability of mirabegron in pediatric participants with OAB and evaluated the pharmacokinetics after multiple dose administration of mirabegron in pediatric participants with OAB.

Additional Study Details

Phase
Phase 3
Product
  • Mirabegron
  • Placebo
  • Type
    Interventional
    Masking
    Double (Participant, Investigator)
    Enrollment number
    26
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English
    Protocol
    Available Language(s): English
    Statistical Analysis Plan (SAP)
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A study to evaluate mirabegron in pediatric participants from 5 to less than 18 years of age with overactive bladder (OAB)? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Withdrawn
      Site ML60002
      Kuala Lumpur, Malaysia, 50586
      Withdrawn
      Site ML60003
      Penang, Malaysia, 10990
      Withdrawn
      Site KR82001
      Seoul, Seoul Teugbyeolsi, Republic of Korea, 5505
      Withdrawn
      Site KR82002
      Seoul, Seoul Teugbyeolsi, Republic of Korea, 3080
      Withdrawn
      Site KR82003
      Seoul, Seoul Teugbyeolsi, Republic of Korea, 3772
      Completed
      Site KR82004
      Yangsan-Si, Gyeongsangnamdo, Republic of Korea, 50612
      Withdrawn
      Site NL31001
      Deventer, Overijssel, Netherlands, 7416 SE
      Completed
      Site RU70001
      Kazan, Tatarstan, Respublika, Russian Federation, 420138
      Completed
      Site TR90001
      Bursa, Bursa, Turkey, 16059
      Withdrawn
      Site CA15006
      London, Ontario, Canada, ON N6A 5W9
      Withdrawn
      Site PH63002
      Angeles City, Philippines, 2009
      Withdrawn
      Site PH63004
      Cebu City, Philippines, 6000
      Withdrawn
      Site PH63005
      Quezon City, Philippines, 1113
      Withdrawn
      Site PH63007
      Davao City, Philippines, 8000
      Withdrawn
      Site RU70008
      Yekaterinburg, Russian Federation, 620134
      Withdrawn
      Site TR90003
      Mersin, Içel, Turkey, 33343
      Withdrawn
      Site BE32002
      Kortrijk, Belgium, 8500
      Withdrawn
      Site ML60001
      Kuala Lumpur, Malaysia, 59100
      Withdrawn
      Site ZA27003
      Pretoria, Gauteng, South Africa, 0001
      Withdrawn
      Site UA38007
      Ivano-Frankivsk, Ukraine, 76014
      Withdrawn
      Site DE49002
      Moenchengladbach, Germany, 41063
      Withdrawn
      Site PH63001
      Quezon City, Philippines, 1105
      Completed
      Site RU70004
      Moscow, Moskva, Russian Federation, 117997
      Withdrawn
      Site UA38008
      Kharkiv, Ukraine, 61075
      Withdrawn
      Site PL48001
      Piaseczno, Poland, 05-500
      Withdrawn
      Site PH63006
      Quezon City, Philippines, 1100
      Withdrawn
      Site FR33003
      Amiens, France, 80000
      Withdrawn
      Site FR33004
      Nice, France, 06200
      Withdrawn
      Site GB44004
      Reading, Berkshire, United Kingdom, RG1 5AN
      Withdrawn
      Site BE32005
      Gent, Belgium
      Withdrawn
      Site NO47001
      Bergen, Norway
      Withdrawn
      Site ES34003
      Santiago de Compostela, Spain
      Withdrawn
      Site BE32001
      Edegem, Belgium, 2650
      Withdrawn
      Site FR33002
      Paris, France, 75015
      Withdrawn
      Site FR33001
      Marseille, France, 13005
      Withdrawn
      Site RU70002
      Moscow, Russian Federation
      Withdrawn
      Site RU70005
      Moscow, Russian Federation
      Withdrawn
      Site BE32004
      Antwerpen, Belgium
      Withdrawn
      Site DK45002
      Aalborg, Denmark
      Withdrawn
      Site MX52001
      Ciudad de Mexico            , Mexico
      Withdrawn
      Site MX52003
      Nuevo León                     , Mexico
      Withdrawn
      Site NO47002
      Stavanger, Norway
      Withdrawn
      Site NO47003
      Lorenskog, Norway
      Withdrawn
      Site GB44003
      Newcastle Upon Tyne, United Kingdom
      Withdrawn
      Site GB44005
      Nottingham, United Kingdom
      Withdrawn
      Site GB44006
      London, United Kingdom

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?